As of June, 4 Sonoma Pharmaceuticals, Inc. (SNOA) EPS Estimated At $-0.65

May 17, 2018 - By Susanne Funderburg

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA)’s earnings report is expected on June, 4., RTT reports. EPS of $-0.65 is 5.80 % up from 2017’s $-0.69 EPS. -10.96 % EPS growth is what Wall Street’s predicts after $-0.73 reported EPS previous quarter. SNOA is reaching $3.78 during the last trading session, after decreased 1.05%.Sonoma Pharmaceuticals, Inc. has volume of 11,989 shares. Since May 17, 2017 SNOA has declined 45.71% and is downtrending. The stock underperformed the S&P 500 by 57.26%.

Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in the United States, Latin America, Europe, and internationally.The firm is valued at $17.93 million. The firm offers Microcyn line of products that are based on electrically charged oxychlorine small molecules designed to target a range of pathogens, such as viruses, fungi, and spores, as well as bacteria, including antibiotic-resistant strains.Last it reported negative earnings. The Company’s products also include Celacyn, a prescription hypochlorous acid based scar management gel; Ceramax Skin Barrier Cream to manage dry itchy skin, minor skin irritations, rashes, and inflammation; Mondoxyne, a prescription oral tetracycline antibiotic for the treatment of various bacterial infections; Alevicyn, a prescription hypochlorous acid based atopic dermatitis product line to reduce itch and pain associated with various dermatoses; and SebuDerm, a prescription topical gel for the management of burning, itching, and scaling in seborrhea and seborrheic dermatitis.

More recent Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) news were released by Streetinsider.com, Globenewswire.com and Globenewswire.com. The first one has “Sonoma Pharmaceuticals (SNOA) Appoints Marc Umscheid COO” as a title and was released on May 08, 2018. The next is “Sonoma Pharmaceuticals Receives Four New UAE Regulatory Approvals that Include Acne and Anti-Fungal Products” on April 17, 2018. And last was released on May 08, 2018, called “Sonoma Pharmaceuticals Names Marc Umscheid Chief Operating Officer”.

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: